Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967

Modes of p53 regulation.

Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610

Physiochemical drug properties associated with in vivo toxicological outcomes

Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946

A General and Efficient Copper Catalyst for the Amidation of Aryl Halides

Klapars, A., Huang, X. S., & Buchwald, S. L. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0260465 · Cited by 855

Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Zhao, C., Zeng, C., Wang, K., He, Q., Yang, B., Zhou, F., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0441-3 · Cited by 18

Chromatin Ubiquitination Guides DNA Double Strand Break Signaling and Repair

Kolobynina, K. G., Rapp, A. W., & Cardoso, M. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.928113 · Cited by 17

Crystallographic mining of ASK1 regulators to unravel the intricate PPI interfaces for the discovery of small molecule

Agrahari, A. K., Dikshit, M., & Asthana, S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.008 · Cited by 18

Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02057-8 · Cited by 17

Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 17

Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

Aguilar, A., Yang, J., Li, Y., McEachern, D., Huang, L., Razzouk, S., & Wang, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01818 · Cited by 16

Effective modification of cell death-inducing intracellular peptides by means of a photo-cleavable peptide array-based screening system

Kozaki, I., Shimizu, K., & Honda, H. (2017) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2017.03.013 · Cited by 16

BET bromodomain inhibitors regulate keratinocyte plasticity

Schutzius, G., Kolter, C., Bergling, S., Tortelli, F., Fuchs, F., Renner, S., Guagnano, V., Cotesta, S., Rueeger, H., Faller, M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00716-z · Cited by 17

Query-guided protein–protein interaction inhibitor discovery

Celis, S., Hóbor, F., James, T., Bartlett, G. J., Ibarra, A. Á., Shoemark, D. K., Hegedüs, Z., Hetherington, K., Woolfson, D. N., Sessions, R. B., et al. (2021) · Chemical Science · doi:10.1039/d1sc00023c · Cited by 17

From High-Throughput Screening to Target Validation: Benzo[d]isothiazoles as Potent and Selective Agonists of Human Transient Receptor Potential Cation Channel Subfamily M Member 5 Possessing In Vivo Gastrointestinal Prokinetic Activity in Rodents

Barilli, A., Aldegheri, L., Bianchi, F., Brault, L., Brodbeck, D., Castelletti, L., Feriani, A., Lingard, I., Myers, R., Nola, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00065 · Cited by 16

Investigation of the In-Vivo Cytotoxicity and the In Silico-Prediction of MDM2-p53 Inhibitor Potential of Euphorbia peplus Methanolic Extract in Rats

Abd‐Elhakim, Y. M., NASSAN, M. A., Salem, G. A., Sasi, A., Aldhahrani, A., Issa, K. B., & Mohamed, A. A.-R. (2019) · Toxins · doi:10.3390/toxins11110642 · Cited by 16

Design, synthesis, and molecular modeling of coumarin derivatives as MDM2 inhibitors targeting breast cancer

Ahmed, E. Y., Latif, N. A. A., Nasr, T., Awad, H. M., & Abdelhafez, O. M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14028 · Cited by 14

Design, synthesis and structure–activity relationship of 4,5-dihydropyrrolo[3,4- c ]pyrazol-6(1 H )-ones as potent p53-MDM2 inhibitors

Zhou, W.-H., Xu, X., Li, J., Min, X., Yao, J., Dong, G., Zhuang, C., Miao, Z., & Zhang, W. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.09.001 · Cited by 14

Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning

Yang, W., Wang, J., Zhao, L., & Chen, J. (2024) · Molecules · doi:10.3390/molecules29143377 · Cited by 15

Decoding the Role of MDM2 as a Potential Ubiquitin E3 Ligase and Identifying the Therapeutic Efficiency of Alkaloids against MDM2 in Combating Glioblastoma

Sharma, S., & Kumar, P. (2023) · ACS Omega · doi:10.1021/acsomega.2c07904 · Cited by 15

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

Zhang, X., Meng, T., Cui, S., Feng, L., Liu, D., Pang, Q., & Wang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621294 · Cited by 14

Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge

Chêne, P. (2024) · ChemMedChem · doi:10.1002/cmdc.202400361 · Cited by 12

Syntheses of 4-allyl-/4-allenyl-4-(arylthio)-1,4-dihydroisoquinolin-3-ones via the photochemical Doyle–Kirmse reaction

Xie, J., Suleman, M., Wang, Z., Mao, X., Mao, B., Fan, J., Lü, P., & Wang, Y. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob00859e · Cited by 12

MDM2 inhibition is synthetic lethal with PTEN loss in colorectal cancer cells via the p53-dependent mechanism

Ren, G., Yang, E. J., Tao, S., Mou, P. K., Pu, Y., Chen, L., & Shim, J. S. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82566 · Cited by 12

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Si, D., Luo, H., Zhang, X., Yang, K., Wen, H., Li, J., & Li, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105268 · Cited by 12

Perspectives on drug discovery strategies based on IDPs

Fuertes, G., Nevola, L., & Esteban-Martín, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816348-1.00009-0 · Cited by 11

The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia

Tan, B., Tong, C., Yuan, Y., Xu, P. A., Wen, L., Zhang, C., Zheng, Y., Lin, L. W., Zhu, F., Gui, S., et al. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000023 · Cited by 11

MDM2 promotes the proliferation and inhibits the apoptosis of pituitary adenoma cells by directly interacting with p53

Wang, Y., Zhao, J., Zhang, C., Wang, P., Huang, C., & Peng, H. F. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0053 · Cited by 11

Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema

Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 10

Protein Degradation by E3 Ubiquitin Ligases in Cancer Stem Cells

Quiroga, M., Rodríguez-Alonso, A., Alfonsín, G., Escuder‐Rodríguez, J.-J., Breijo, S. M., Chantada, V., & Figueroa, A. (2022) · Cancers · doi:10.3390/cancers14040990 · Cited by 10

Focused Library Generator: case of Mdmx inhibitors

Xia, Z., Karpov, P., Popowicz, G. M., & Tetko, I. V. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00242-8 · Cited by 10

Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration

Jeong, S., Cha, J., Ahmed, W., Kim, J., Kim, M., Hong, K. T., Choi, W., Choi, S., Yoo, T. H., An, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415626 · Cited by 9

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Zanjirband, M., Rahgozar, S., & Aberuyi, N. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.113 · Cited by 9

Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

Kang, J. H., Lee, S.-H., Lee, J., Oh, S. J., Ha, J. S., Choi, H.-J., & Kim, S. (2020) · Cells · doi:10.3390/cells9061475 · Cited by 9

Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold

Albadari, N. G., Xie, Y., Liu, T., Wang, R., Gu, L., Zhou, M., Wu, Z., & Li, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115423 · Cited by 8

Phosphoryl chloride-mediated solvent-free synthesis of N-aryl-substituted azacycles from arylamines and cyclic ethers

Trần, V. H., La, M. T., & Kim, H. (2019) · Tetrahedron Letters · doi:10.1016/j.tetlet.2019.06.019 · Cited by 8

Synthesis of 1‐Aryl Isoquinolinones or o‐Diaryl Pyrimidines via Bismuth Triflate‐Mediated Intermolecular Annulation of Arylacetic Acids with Nitroarylaldehydes or Trimethoxybenzene in the Presence of Acetonitrile

Chang, M., Lin, C., & Chen, S.-M. (2022) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202200517 · Cited by 8

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours

Chen, L., Esfandiari, A., Reaves, W., Vu, A. T., Hogarty, M. D., Lunec, J., & Tweddle, D. A. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4261 · Cited by 8

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Lin, Z., Liu, C., Yan, Z., Cheng, J., Wang, X., Zhou, F., Lyu, X., Zhang, S., Zhang, D., Meng, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116366 · Cited by 7

Photochemical synthesis of an epigenetic focused tetrahydroquinoline library

Green, A. I., & Burslem, G. M. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00193k · Cited by 7

MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7

The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy

Yu, B., & Liu, H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_8 · Cited by 6

PPAR Modulation Through Posttranslational Modification Control

Videira, N. B., Dias, M. M. G., Terra, M. F., de Oliveira, V. M., García‐Arévalo, M., Avelino, T. M., Torres, F. R., Batista, F. A. H., & Figueira, A. C. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_21 · Cited by 7

A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT

Siriki, A., Ragland, G., Vasireddy, J., & Chitneni, S. K. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130394 · Cited by 7

Targeting MDM2 for the development of a new cancer therapy: progress and challenges

Aguilar, A., Thomas, J. E., & Wang, S. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03102-1 · Cited by 6

Highly Enantioselective Synthesis of Polycyclic Dihydroisoquinolinones via NHC-Catalyzed [4 + 2] Annulations

Ren, X., Duan, X.-Y., Feng, Y., Li, Y., Li, J., & Qi, J. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01529 · Cited by 6

Improving Speed and Affordability without Compromising Accuracy: Standard Binding Free-Energy Calculations Using an Enhanced Sampling Algorithm, Multiple-Time Stepping, and Hydrogen Mass Repartitioning

Blazhynska, M., de Lacam, E. G. C., Chen, H., & Chipot, C. J. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00141 · Cited by 6

FMO Drug Design Consortium

Fukuzawa, K., Tanaka, S., Yagi, Y., Kurita, N., Kawashita, N., Takaba, K., & Honma, T. (2021) · Springer eBooks · doi:10.1007/978-981-15-9235-5_8 · Cited by 5

The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation

Zhang, X., Zhou, C., Yang, Y., Liu, H., Wang, S., Ding, X., & Hu, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202100517 · Cited by 5

Cellular Senescence in Diffuse Gliomas: From Physiopathology to Possible Treatments

Ordóñez-Rubiano, E. G., Cómbita, A. L., Baldoncini, M., Payán‐Gómez, C., Gómez-Amarillo, D. F., Hakim, F., Camargo, J., Zorro-Sepúlveda, V., Luzzi, S., Zorro, Ó., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.08.060 · Cited by 6

Role of Sex in the Therapeutic Targeting of p53 Circuitry

Mancini, F., Giorgini, L., Teveroni, E., Pontecorvi, A., & Moretti, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698946 · Cited by 5

Elucidation of Conformational Dynamics of MDM2 and Alterations Induced Upon Inhibitor Binding Using Elastic Network Simulations and Molecular Docking

Kantarci-Carsibasi, N. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500460 · Cited by 4

Protein–Protein Interaction Inhibitors in Cancer

Hardcastle, I. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12392-3 · Cited by 5

Protein–Protein Interaction Inhibitors

Hardcastle, I. R. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_27 · Cited by 4

Understanding Protein–Protein Interactions: Essential Players in (Patho)physiology (Part 1)

Wilson, A. J., & Gunning, P. T. (2016) · ChemBioChem · doi:10.1002/cbic.201600166 · Cited by 4

Integrative machine learning approach for identification of new molecular scaffold and prediction of inhibition responses in cancer cells using multi-omics data

Kaushik, A. C., Talware, S. K., & Siddiqi, M. I. (2025) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaf006 · Cited by 3

The evolution of Nutlins as p53-MDM2 inhibitors

Bazanov, D. R., & Lozinskaya, N. A. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03492-4 · Cited by 3

Chemical adaptation: bridging synthetic chemistry with drug development

Ding, K., Li, Y., Zhou, Y., & Huang, W. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3223-4 · Cited by 3

Interaction Analysis by Fragment Molecular Orbital Method for Drug Discovery Research

Kawashita, N. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00448 · Cited by 3

Bioorthogonal Probes for the Study of MDM2‐p53 Inhibitors in Cells and Development of High‐Content Screening Assays for Drug Discovery

D’Alessandro, P. L., Buschmann, N., Kaufmann, M., Furet, P., Baysang, F., Brunner, R., Marzinzik, A. L., Vorherr, T. E., Stachyra, T., Ottl, J., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201608568 · Cited by 3

Virtual Screening of Indonesian Herbal Database as Murine Double Minute-2 (MDM2) Inhibitor

Victory, A., Syahdi, R. R., & Yanuar, A. (2018) · Pharmacognosy Journal · doi:10.5530/pj.2018.6.203 · Cited by 3

Artificial Peptide and Protein Receptors

Hatai, J., & Schmuck, C. (2019) · Wiley eBooks · doi:10.1002/9783527814923.ch3 · Cited by 3

CF2H: a cell-free two-hybrid platform for rapid protein binder screening

Capin, J., Mayonove, P., DeVisch, A., Becher, A., Ngo, G., Courbet, A., Ragotte, R. J., Cohen‐Gonsaud, M., Espeut, J., & Bonnet, J. P. (2026) · Nature Communications · doi:10.1038/s41467-026-69741-1 · Cited by 2

Drug Design Methods to Regulate Protein–Protein Interactions

Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 2

Designer polyQ fusion proteins sequester USP7/HDM2 for modulating P53 functionality

Zhang, X., Yue, H.-W., Liu, Y., Wang, J., Duan, H.-T., Liu, Y.-H., Jiang, L., & Hu, H. (2025) · iScience · doi:10.1016/j.isci.2025.112025 · Cited by 3

15.6.3 Isoquinolinones (Update 2018)

Александрович, Г. В., & Shklyaev, Y. V. (2018) · Haug Verlag in Georg Thieme Verlag KG eBooks · doi:10.1055/sos-sd-115-00563 · Cited by 2

Sc(OTf)3-promoted formal insertion of 4-diazo-1,4-dihydroisoquinolin-3-ones into C–H bond of 1,3-dicarbonyl compounds: Synthesis of 2-(3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)-1,3-diarylpropane-1,3-diones

Xie, J., Suleman, M., Qian, G., Lü, P., & Wang, Y. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133558 · Cited by 2

Chemo- and Diastereoselective Entries into All-Carbon α-Quaternary Aldehydes via C–C Insertion of 4-Diazoisoquinolin-3-ones into C–CHO Bonds

Levashova, E., Adamchik, M., Kantin, G. P., & Dar’in, D. V. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01222 · Cited by 2

Cell Death of Tumor Melanocytes and Treatment Options

Koval, O. A., Zhilnikova, M., Balantaeva, M., Biryukov, M., & Atamanov, V. V. (2025) · Biocell · doi:10.32604/biocell.2025.059987 · Cited by 2

Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects

Han, Y., Ren, Z., Wu, Y., Chen, Y., Cui, Z., Zhu, T., Ma, M., Du, Y., & Dong, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.122 · Cited by 2

An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors

Xue, X., Bao, G., Zhang, H.-Q., Zhao, N.-Y., Sun, Y., Zhang, Y., & Wang, X. (2018) · Molecules · doi:10.3390/molecules23123174 · Cited by 2

BCl 3 catalyzed Z -selective intramolecular chlorocarbamoylation of alkynes/allenes

Yang, Z., Chen, L., Zhao, Y., Chen, Q., Zhao, W., Li, L., Zhang, B., Xie, H., Kong, X., & Yang, C. (2024) · Organic Chemistry Frontiers · doi:10.1039/d4qo01487a · Cited by 1

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

Granados, M. L., Cozzubbo, S., Porro, M., Cumerlato, M., Bandini, C., Mereu, E., Paradžik, T., Donati, B., Manicardi, V., Ronchetti, D., et al. (2026) · Cells · doi:10.3390/cells15090831 · Cited by 1

Dynamic ubiquitination networks in liver cancer: decoding E3 ligases and deubiquitinases as gatekeepers of therapeutic resistance

Xu, N., Tong, Y., Ma, K., Jiang, L., & Zheng, W. (2025) · Medical Oncology · doi:10.1007/s12032-025-02912-0 · Cited by 1

Discovery of N-pyridazin-3-piperidine derivatives acting as p53 activators against breast cancer: In vitro and in silico evaluations

Zhang, A., Tang, B., Zhou, S., Sui, C., He, S., Liu, Y., Li, M., & Qian, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118410 · Cited by 1

Pharmacophore Modeling Guided by Conformational Dynamics Reveals Potent Anticancer Agents

Kantarci-Carsibasi, N. (2023) · Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.19113/sdufenbed.1121167 · Cited by 1

Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction

Hu, M. Y., Xu, C., Xu, M., He, S., & Liu, D. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206358340250121060830 · Cited by 1

Synthetic approaches to N- and 4-substituted 1,4-dihydro-3(2H)-isoquinolinone derivatives

Sullivan, M. J. O., Hatley, R. J. D., Wellaway, C. R., Bew, S. P., & Richards, C. J. (2021) · Tetrahedron · doi:10.1016/j.tet.2021.132455 · Cited by 1

Enhancing structure-based virtual screening of MDM2–p53 inhibitors: a benchmark of machine learning vs. traditional docking scoring functions

Tarazona, M. Y. C., & Miscione, G. P. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1731262 · Cited by 1

Computational Methods Applicable to the Discovery of Small-Molecule Inhibitors of Protein-Protein Interactions

Han, L., & Wang, R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_4

Cyclization strategies to stabilize epidermal growth factor receptor dimerization arm mimics

Hanold, L. E. (2016)

Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction

Li, Y. (2018) · Deep Blue (University of Michigan)

Facile Metal-Free Direct Transformation of N-Allyl- and tert-Butyl-Protected Arylamines to Azacycles Using Phosphoryl Chloride and TBDPreprint

Trần, V. H., Hong, W. P., & Kim, H. (2020) · doi:10.3762/bxiv.2020.123.v1

Discovery of AMG 232, a Small Molecule MDM2 Inhibitor in Clinical Development and its Back-up Clinical Candidate, AM-7209

Rew, Y., & Eksterowicz, J. E. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00280

Cancer Targets Involving the Ubiquitin Proteasome System

Araujo, E. M. V. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc282

Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation and Binding affinity predicationPreprint

Cao, F., Chen, L., Xiong, F., Liu, X., & Zhang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-905935/v1

O bi namo ma ronga isi go Galelaka / ditulis Etha Yosafat ; diindonesiakan Robinon Ipol

Etha, Y. (1985)

Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation, Binding affinity predication and Cell AssayPreprint

Cao, F., Liang, C., Xiong, F., Li, H., Liu, X., & Zhang, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1410429/v1

Synthesis and Mechanism of p53‐MDM2 Inhibitors with Heterocyclic Structures: A Focused Review

Ji, L., Zhang, W., Zhang, Y., Zhao, S., Long, H., Qin, L., Tian, J., Li, H., Zhu, D., Zhou, Y., et al. (2023) · ChemistrySelect · doi:10.1002/slct.202302240

Additional file 8 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128586

Additional file 3 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128571

Additional file 1 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128565

Additional file 7 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128583

Additional file 4 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128574

Additional file 6 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128580

Additional file 5 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128577

Additional file 2 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Ding, L. J., Zhang, Z., Zhao, C., Chen, L., Chen, Z., Zhang, J., Liu, Y., Nie, Y., He, Y., Liao, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15128568

Computational Methods and Tools for the Design and Development of Small Molecule Inhibitors Targeting PPIs

Chowdhury, A., & Murru, S. (2026) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-032-07880-3_6

Protein-protein interaction inhibitors in cancer

Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4

Conception et évaluation de peptides inhibiteurs de l'interaction ribosomale hCINAP/RPS14 dans un but antitumoral

Duflocq, S. (2021) · theses.fr (ABES) · doi:10.70675/ef227c50z2ceez459dzb908z9a4d36e0af98

Bases moléculaire de l'interaction protéine-protéine lors de la synaptogenèse

de Lacam, E. G. C. (2023) · theses.fr (ABES) · doi:10.70675/6f0af6e8z43cdz4f3czb462z86c0726d15b4

Modeling and Standard Binding Free Energy Calculations of Complex Biological Objects

Blazhynska, M. (2023) · theses.fr (ABES) · doi:10.70675/48e8ac59z3fecz4841za036z40e6a446b0cc

Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies

Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264

A Prominent Candidate in Natural Product Discovery for Multi-Target Cancer Therapy: Structure-Based Assessment of Hyperforin

Aydın, G. (2025) · Kastamonu University Journal of Engineering and Sciences · doi:10.55385/kastamonujes.1824730

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs

Holzer, P. (2017) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2017.716 · Cited by 28

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Jeay, S., Berghausen, J., Buschmann, N., Chêne, P., Cozens, R. M., Erdmann, D., Ferretti, S., Furet, P., Gabriel, T., Gessier, F., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1797 · Cited by 4

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Furet, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

Vaupel, A., Holzer, P., Ferretti, S., Guagnano, V., Kallen, J. A., Mah, R., Masuya, K., Ruetz, S., Rynn, C., Schlapbach, A., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.08.027 · Cited by 22

Mechanistic study of NVP-CGM097: A potent, selective and species specific inhibitor of p53-Mdm2

Valat, M. T. (2015) · Drug Designing Open Access · doi:10.4172/2169-0138.s1.008 · Cited by 8